Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
1,923,038
result(s) for
"Biotechnology industries"
Sort by:
Research Methodology and Project Management in Biotechnology
Research Methodology and Project Management in Biotechnology is a vital resource addressing core concepts in the dynamic field of biotechnology. This comprehensive textbook focuses on research methodology, techniques, and project management, and provides essential knowledge for students and faculty in life sciences and allied disciplines. Key features of the book include learning objectives, self-assessments and exercises, and a simple presentation (using bullet points, tables, and figures) designed to assist comprehension and retention of key information. The book is split into 5 units with 12 focused chapters: Unit I: Molecular Biology TechniquesCovers various techniques used in molecular biology, including nucleic acid isolation, DNA fragmentation, PCR, DNA sequencing, and more.Unit II: Scientific Communication and LiteratureIntroduces the process of research writing.Unit III: Biotechnology Entrepreneurship and MarketingCovers the role of funding, intellectual property rights, and regulations.Unit IV: Genomics, Proteomics, and BioinformaticsExplores DNA sequencing strategies, gene expression analysis, and the role of bioinformatics in drug discovery.Unit V: Advanced Biotechnological TechniquesCovers topics such as antisense technology, molecular cytogenetics, pharmacogenomics, next-generation DNA sequencing, and ethical considerations in science and technology.Unit VI: Medical BiotechnologyCovers disease detection and diagnosis, genetic diseases, personalized medicine, nanotechnology, gene therapy, regenerative medicine, and the Human Genome Project. This textbook is suitable for courses aimed to enhance biotechnology project planning and execution skills and building a professional career path in biotechnology. Readership Students and faculty in life sciences and allied courses.
eBook
Betting on Biotech
After World War II, several late-developing countries registered astonishingly high growth rates under strong state direction, making use of smart investment strategies, turnkey factories, and reverse-engineering, and taking advantage of the postwar global economic boom. Among these economic miracles were postwar Japan and, in the 1960s and 1970s, the so-called Asian Tigers-Singapore, South Korea, and Taiwan-whose experiences epitomized the analytic category of the \"developmental state.\"
InBetting on Biotech, Joseph Wong examines the emerging biotechnology sector in each of these three industrial dynamos. They have invested billions of dollars in biotech industries since the 1990s, but commercial blockbusters and commensurate profits have not followed. Industrial upgrading at the cutting edge of technological innovation is vastly different from the dynamics of earlier practices in established industries.
The profound uncertainties of life-science-based industries such as biotech have forced these nations to confront a new logic of industry development, one in which past strategies of picking and making winners have given way to a new strategy of throwing resources at what remain very long shots. Betting on Biotech illuminates a new political economy of industrial technology innovation in places where one would reasonably expect tremendous potential-yet where billion-dollar bets in biotech continue to teeter on the brink of spectacular failure.
eBook
Just how good an investment is the biopharmaceutical sector?
An analysis of biotech and pharma stock prices since 1930 reveals sharp differences in the risk-adjusted returns of the two sectors.
Uncertainty surrounding the risk and reward of investments in biopharmaceutical companies poses a challenge to those interested in funding such enterprises. Using data on publicly traded stocks, we track the performance of 1,066 biopharmaceutical companies from 1930 to 2015—the most comprehensive financial analysis of this sector to date. Our systematic exploration of methods for distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate classification method. We find that the performance of the biotech sector is highly sensitive to the presence of a few outlier companies, and confirm that nearly all biotech companies are loss-making enterprises, exhibiting high stock volatility. In contrast, since 2000, pharmaceutical companies have become increasingly profitable, with risk-adjusted returns consistently outperforming the market. The performance of all biopharmaceutical companies is subject not only to factors arising from their drug pipelines (idiosyncratic risk), but also from general economic conditions (systematic risk). The risk associated with returns has profound implications both for patterns of investment and for funding innovation in biomedical R&D.
Journal Article
Biotech’s baby boom
2018 was the year when the funding machine for privately held biotech companies went into overdrive, with mega-rounds and rapid flotations. John Hodgson brings us this deep dive.
Journal Article